A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation.

NCT07456046 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

KRAS P.G12D

Interventions

DRUG: D3S-003

Sponsor

D3 Bio (Wuxi) Co., Ltd